BioLineRx Expands Pipeline, Pursues Oral HCV Treatment
Another hepatitis C candidate knocked the socks off investors Tuesday as Jerusalem's BioLineRx Ltd. added a new prong to its pipeline, inking a worldwide, exclusive license agreement with the French firm Genoscience to develop and commercialize the orally available protease inhibitor (PI) BL-8020.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter